FDA announcement in RettSyndrome.com
Also helps ease some doubt on the effectiveness of the phase 2 study
“Results from a previous Neuren-sponsored Phase 2 trial (NCT02715115) in 82 girls ages 5 to 15 with Rett syndrome revealed that the highest dose tested (200 mg/kg) was safe and significantly eased a range of Rett’s core symptoms, compared with a placebo.”
https://rettsyndromenews.com/2020/0...designation-to-trofinetide-for-rett-syndrome/
Ann: Rare Pediatric Disease designation received from FDA, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$17.11 |
Change
-0.180(1.04%) |
Mkt cap ! $2.159B | |||
| Open | High | Low | Value | Volume |
| $17.08 | $17.67 | $16.97 | $3.026M | 174.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 370 | $17.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.12 | 22 | 1 |
View Market Depth
| Last trade - 11.46am 01/08/2025 (20 minute delay) ? |
| NEU (ASX) Chart |